Cellectis SA (ADR)(NASDAQ: CLLS) stock surged over 10.6% on March 14th, 2018 (as of 11:34AM EDT; Source: Google finance) leading to over 30.6% in the last three months.
For FY17, the revenues rose to $34 million from $56 million in pcp. The Collaboration revenues fell by $19 million, which was notably explained by $8 million one-time milestones revenue recorded during the second quarter of 2016 in connection with UCART19, $6 million fall in revenue recognition of upfront payments, and $5 million fall in revenue of research and development services and supply of UCART19 products.
The group has built a foundation for the last five years and would reach a turning point in 2019, reaching expansion phase and extending their leading into the allogeneic CAR T-cell field together with their partners.
At present, the group is manufacturing their third product UCART22, which is set to enter clinical trial in the second half of this year in ALL and non-Hodgkin lymphoma. In 2018, they would build up on the clinical proof-of-concept of the selected UCART platform started almost three years ago with UCART19, by advancing their wholly-owned product candidate UCART123 and UCART22 through clinical trials.
By the end of this year, three of the off-the-shelf CAR T product candidates would be in the clinic with their wholly-owned UCART123 and UCART22 programs as well as partnered with UCART19. For 2019, the group would have two different oncology programs, ALL, AML and an expansion phase, and expect to advance an additional UCART product candidate into clinical development with UCARTCS1 and UCARTCLL1. The group would continue the robust development of the best-in-class manufacturing process of their next-generation CAR T therapeutics, including implementing our proprietary gene-targeted gene insertion technology into our pipeline of product candidates. The group intends to finish these dose escalation phase for UCART123 within the next 12-months before moving into the expansion phase in 2019, where they plan to enroll-up up to 150 AML and BPDCN patients.
The group had $297 million in cash, as of Dec 2017 from $291 million as of December 31, 2016. This rise comprises $38 million proceeds received as part of the Calyxt IPO, $7 million proceeds from the sale and leaseback transaction at Calyxt, $15 million of positive ForEx impact on cash flows, which were partially offset by $52 million net cash flows used by operating activities.